StockData
Avenue Therapeutics, Inc. logo

Avenue Therapeutics, Inc. (ATXI) shareholders

ATXIOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 4/30
$0.43+0.00 (0.00%)

Close on Oct 16, 2026Market cap $1.42MP/E –Yield –

Ownership

Institutional holdings as of Mar 31, 2025, from 13F filings

Held by institutions
0.0%
0M of 3M shares
Institutional holders
0
0 new, 7 sold out
Net institutional buying
-0M
In Q1 2025
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Fortress Biotech, Inc.439,95513.40%13D (active) amendmentJan 2, 2026

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q1 202500M0.0%0 / 00 / 70M0M
Q4 202470M5.8%3 / 31 / 40M0M
Q3 202480M6.0%1 / 51 / 10M0M
Q2 202490M3.5%9 / 00 / 00M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Neil HerskowitzDirector970.00%Dec 3, 2024
Fortress Biotech, Inc.10% owner439,73313.35%Jan 6, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Fortress Biotech, Inc.
10% owner
Jan 2, 2026Award+111,209––439,733
Fortress Biotech, Inc.
10% owner
Mar 31, 2025Award+33,724––328,524
Neil Herskowitz
Director
Dec 2, 2024Sale−23$2.00$4697
Jay D. Kranzler
Director
Nov 5, 2024Sale−61$2.24$137559
Jay D. Kranzler
Director
Sep 30, 2024Buy+497$2.50$1.24K620
Jay D. Kranzler
Director
Sep 27, 2024Buy+3$2.40$7123
David Jin
Interim PFO and COO
Sep 23, 2024Award+65,000––65,000
Alexandra MacLean
Chief Executive Officer, Director
Sep 23, 2024Award+170,000––170,000
Fortress Biotech, Inc.
10% owner
Apr 16, 2024Award+413,507––3,547,393
Fortress Biotech, Inc.
10% owner
Jan 2, 2024Award+2,101,496––3,133,886
Robert L. Davidow
10% owner
Dec 11, 2023Sale−264,000$0.14$36.96K681,000
Robert L. Davidow
10% owner
Dec 11, 2023Sale−20,000$0.14$2.80K80,000
Robert L. Davidow
10% owner
Dec 11, 2023Sale−18,000$0.15$2.70K22,000
Robert L. Davidow
10% owner
Dec 11, 2023Sale−61,000$0.14$8.54K74,000
Robert L. Davidow
10% owner
Dec 11, 2023Sale−126,000$0.14$17.64K215,800
Robert L. Davidow
10% owner
Dec 11, 2023Sale−128,000$0.14$17.92K147,000
Fortress Biotech, Inc.
10% owner
Sep 8, 2023Buy+418,410$0.72$301.26K1,032,390
Lindsay A. Rosenwald Md
Director
Sep 8, 2023Buy+348,675$0.72$251.05K354,318
Fortress Biotech, Inc.
10% owner
Mar 31, 2023Award+52,419––613,980
Fortress Biotech, Inc.
10% owner
Jan 3, 2023Award+231,316––561,561
Fortress Biotech, Inc.
10% owner
Dec 31, 2022Award+90,909––330,245
InvaGen Pharmaceuticals, Inc.
10% owner
Oct 11, 2022Sale−388,888$7.71$3.00M0
Jay D. Kranzler
Director
Dec 17, 2021Award+49,020––113,683
Jay D. Kranzler
Director
Dec 17, 2021Award+20,000––133,683
Curtis Gale Oltmans
Director
Dec 17, 2021Award+49,020––49,020
Neil Herskowitz
Director
Dec 17, 2021Award+20,000––183,744
Neil Herskowitz
Director
Dec 17, 2021Award+49,020––163,744
Joseph Walter Vazzano
Chief Financial Officer
Dec 17, 2021Award+100,505––165,757
Lucy Lu
President, CEO, Director
Dec 17, 2021Award+411,616––748,949
Joseph Walter Vazzano
Chief Financial Officer
Sep 15, 2021Sale−7,160$1.62$11.60K65,252
Neil Herskowitz
Director
May 6, 2021Buy+2,500$3.99$9.98K134,724
Joseph Walter Vazzano
Chief Financial Officer
Aug 20, 2020Sale−3,840$12.13$46.58K57,412
Jay D. Kranzler
Director
Jun 16, 2020Award+10,000––84,663
Neil Herskowitz
Director
Jun 16, 2020Award+10,000––132,224
Joseph Walter Vazzano
Chief Financial Officer
Mar 10, 2020Buy+1,889$7.94$15.00K61,252
Joseph Walter Vazzano
Chief Financial Officer
Mar 9, 2020Buy+1,400$7.99$11.19K59,263
Joseph Walter Vazzano
Chief Financial Officer
Mar 9, 2020Buy+100$7.97$79759,363
Neil Herskowitz
Director
Feb 27, 2020Buy+2,400$8.20$19.68K122,224
Neil Herskowitz
Director
Feb 26, 2020Buy+161$8.73$1.41K119,824
Joseph Walter Vazzano
Chief Financial Officer
Feb 25, 2020Buy+1,200$9.09$10.91K57,863
Neil Herskowitz
Director
Feb 25, 2020Buy+10,000$9.31$93.10K119,663
Elizabeth Garrett Ingram
Director
Sep 12, 2019Buy+16,000$6.27$100.32K16,000
Neil Herskowitz
Director
Aug 27, 2019Award+10,000––109,663
Jay D. Kranzler
Director
Aug 27, 2019Award+10,000––74,663
Joseph Walter Vazzano
Chief Financial Officer
Aug 9, 2019Sale−2,375$5.56$13.20K56,663
Joseph Walter Vazzano
Chief Financial Officer
Aug 8, 2019Sale−2,313$5.62$13.00K59,038
Neil Herskowitz
Director
Jun 18, 2019Buy+2,000$5.83$11.66K99,663
Neil Herskowitz
Director
Jun 17, 2019Buy+3,000$5.88$17.64K97,663
Neil Herskowitz
Director
Apr 15, 2019Buy+1,000$4.52$4.52K94,663
Neil Herskowitz
Director
Mar 29, 2019Buy+1,400$5.11$7.15K93,663
Neil Herskowitz
Director
Mar 28, 2019Buy+600$5.11$3.07K92,263
Neil Herskowitz
Director
Feb 25, 2019Buy+5,000$5.46$27.30K91,663
Neil Herskowitz
Director
Feb 5, 2019Buy+1,850$5.77$10.67K86,663
Neil Herskowitz
Director
Feb 4, 2019Buy+7,000$5.91$41.37K84,813
Neil Herskowitz
Director
Jan 30, 2019Buy+650$5.91$3.84K77,813
Neil Herskowitz
Director
Jan 29, 2019Buy+8,553$5.91$50.55K77,163
Neil Herskowitz
Director
Jan 28, 2019Buy+1,447$5.84$8.45K68,610
Jeffrey Paley
Director
Dec 10, 2018Buy+5,000$4.76$23.80K79,663
Jeffrey Paley
Director
Dec 3, 2018Buy+10,000$5.48$54.80K74,663
Jeffrey Paley
Director
Aug 7, 2018Gift+14,663––64,663

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
0.0%
From 0M shares
Short volume, 20 days
32.9%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Avenue Therapeutics's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

See a number that looks wrong?